SOURCE: Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc.

July 15, 2015 09:25 ET

Cocrystal Pharma Names Walt Addison Linscott, Esq. New General Counsel and Corporate Secretary

BOTHELL, WA and ATLANTA, GA--(Marketwired - July 15, 2015) - Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today the appointment of Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary.

Most recently, Linscott served as Global Strategic Legal Advisor for Thompson Hine, LLP, providing strategic legal advice and business guidance to senior management and Board of Directors of multinational companies focused on the development of consumer products and human health products in complex emerging markets, the U.S. and European Union. Linscott's experience as a lawyer spans 25 years and includes serving as General Counsel and Corporate Secretary of Carestream Health, Inc., a $2.5 billion medical/dental device company, leading as Chair of the Life Sciences practice and office managing partner of an international law firm and serving as the Vice President, General Counsel and Corporate Secretary of a branded pharmaceutical company that was sold to Abbott Laboratories.

"Walt's extensive experience advising and leading multi-national companies within the broad life sciences and biotechnology industries brings tremendous value to our team as we move closer towards bringing our broad-spectrum of antiviral drug candidates into the clinic," stated Interim CEO, Jeffrey Meckler. "Our Board of Directors is committed towards ensuring we move forward with the strongest team in place. Walt's joining helps us ensure that we are positioned for future growth."

About Cocrystal Pharma
Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. For further information about Cocrystal, please refer to www.cocrystalpharma.com.

Contact Information

  • Contact:
    MDM Worldwide
    David Zazoff
    212-643-0417